Retrovirus Center and Virology Section,
Department of Biomedicine, University of Pisa,
Pisa,1 and Department of
Biochemistry and Molecular Biology, University of Ferrara,
Ferrara,2 Italy
The broad resistance to antibody-mediated neutralization of
lentiviruses recently isolated from infected hosts is a poorly understood feature which might contribute to the ability of these viruses to persist and to the failure of experimental vaccines to
protect against virulent viruses. We studied the underlying molecular mechanisms by examining the evolution of a
neutralization-sensitive, tissue culture-adapted strain of feline
immunodeficiency virus upon reinoculation into specific-pathogen-free
cats. Reversion to broad neutralization resistance was observed in
seven of seven inoculated animals and, in individual hosts, started to
develop between less than 4 and more than 15 months from
infection. After comparison of the envelope sequences of the inoculum
virus, of an additional 4 neutralization-sensitive in vitro variants,
and of 14 ex vivo-derived variants (6 neutralization sensitive, 5 resistant, and 3 with intermediate phenotype), a Lys
Asn or
Glu change at position 481 in the V4 region of the surface
glycoprotein appeared as a key player in the reversion.
This conclusion was confirmed by mutagenesis of molecularly
cloned virus. Analysis of viral quasispecies and biological clones
showed that the intermediate phenotype was due to transient
coexistence of neutralization-sensitive and -resistant
variants. Since the amino acid position involved was the same in
four of four recent revertants, it is suggested that the number of
residues that control reversion to broad neutralization resistance in
FIV might be very limited. Amino acid 481 was found to be changed only
in one of three putative long-term revertants. These variants shared a
Ser
Asn change at position 557 in region V5, which probably
collaborated with other mutations in long-term maintenance of
neutralization resistance, as suggested by the study of mutagenized virus.
 |
INTRODUCTION |
Feline immunodeficiency virus (FIV)
is an important pathogen of domestic cats and, due to extensive analogy
to human immunodeficiency virus type 1 (HIV-1), is a valuable model for
AIDS studies (16, 33, 48). Antibody-mediated
neutralization of FIV resembles that of HIV-1. Similarities include (i)
a much greater resistance to neutralizing antibodies of viruses
recently isolated from infected hosts compared to laboratory tissue
culture-adapted (TCA) strains; (ii) an unpredictable sensitivity of
primary isolates to inhibition by heterologous immune sera (6,
14, 27); (iii) a narrow breadth of activity of neutralizing
antibodies; (iv) the presence of an important neutralization linear
determinant in the variable (V) region 3 of the surface
glycoprotein (SU) of TCA strains, whereas the
neutralization epitopes of primary isolates appear to be mainly
conformational (15, 17, 31); and (v) the dependence of
neutralization on the cell substrate used (1, 39). Thus, although the functional domains of its SU and transmembrane
glycoprotein (TM) are much less well characterized than
those of HIV, FIV may help shed light on the mechanisms and role of
antibody-mediated neutralization in lentiviral infections.
We previously reported that, following one 4-month passage in a
specific-pathogen-free (SPF) cat, a highly neutralization-sensitive (NS) TCA strain of FIV had reverted to the broad neutralization resistance typical of primary isolates and that the SU of the revertant
differed from the parental virus at two amino acid positions (469 and
481) within the V4 region (7). However, it remained to be
determined whether reversion to the neutralization-resistant (NR)
phenotype typical of wild-type virus (heretofore indicated as NS
NR
reversion) was a general consequence of readaptation in vivo and, if
so, whether it was associated with constant or diverse amino acid
changes. Here, we show that such reversion is a general occurrence
although, in individual cats, it may take variably long to develop.
Moreover, analysis of numerous in vitro and ex vivo NS and NR variants
as well as of biological and molecular clones has identified amino acid
position 481 of SU as a major player in the reversion.
 |
MATERIALS AND METHODS |
Progenitor and variant viruses.
The progenitor TCA virus was
the Petaluma strain of FIV produced by chronically infected FL4 cells
(49; generous gift of Janet K. Yamamoto). In our
laboratory, FL4 cells are routinely split 1:5 twice weekly. Viral
stocks were obtained by harvesting supernatants at cell passages 181 (stock FL-181), 193 (FL-193), and 381 (FL-381). Female SPF cats (Iffa
Credo, L'Arbresle, France) were infected intravenously with 1 ml of
viral stock FL-193, corresponding to approximately 20 50% cat
infectious doses, when 7 to 12 months old. Virus reisolations were
performed by standard coculture of peripheral blood mononuclear cells
with MBM cells. This line of feline CD3+,
CD4
, and CD8
T lymphocytes is routinely
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum,
5 µg of concanavalin A, and 20 U of recombinant human interleukin-2
per ml. Reisolations varied only slightly in the time that they were
first positive and the levels of reverse transcriptase produced, and
three to five amplifications in MBM cells were sufficient to accumulate
viral stocks of suitable titer. MBM cells were also used to produce
some in vitro variants so that, with three exceptions in which
supernatant of FL4 cultures was used, the virus stocks used in
neutralization assays consisted of MBM cell fluids. The fluids were
clarified at 350 g for 15 min, were stored in 1-ml aliquots in liquid
nitrogen, and were subjected to titer determination at least twice in
quadruplicate by endpoint dilution in a microtiter MBM cell assay after
1 h at 4°C, i.e., with the same incubation conditions used for
the neutralization test. No differences were noted in replication kinetics between the progenitor and variant viruses. Titers ranged between 2 × 102 and 1 × 103 50% tissue
culture infective doses (TCID50) per ml.
Neutralization assay.
Virus neutralization was performed as
previously described (14) against 10 TCID50 of
FIV and MBM cells grown in the presence of 6% pooled normal cat serum
as indicator cells. Immune sera were generally diluted 1:8, 1:32,
1:128, and 1:512 (dilutions before the addition of virus and cells),
and each experiment included controls receiving virus incubated with
identical dilutions of normal cat serum. Neutralizing antibody titers
were defined as the reciprocal of the serum dilution required to reduce
by
50% the levels of reverse transcriptase activity produced in the
presence of the corresponding dilution of normal cat serum and were
calculated according to Reed and Müench (35). All
experiments were repeated at least twice. In general, reproducibility
was satisfactory since titers with a given virus-serum combination
exhibited a maximum twofold deviation between experiments, which is
within the expected error of neutralization assays with the format used.
Criteria for scoring the neutralization phenotype of virus
variants.
The neutralization sensitivity of viral variants was
probed against a panel of 11 heat-inactivated sera taken from eight
FIV-infected cats at varying times postinfection (p.i.; see legend to
Table 1). Based on the neutralization properties of primary FIV
isolates (14), variants were considered NS when they were
neutralized by at least nine test sera with an average titer of
128,
NR if neutralized by no more than four sera with a mean titer of
32, and intermediate (NI) when they exhibited in-between sensitivity.
DNA isolation, sequencing, and genetic analyses.
DNA was
extracted from 6 × 106 infected cells with
phenol-chloroform and was checked for integrity by ethidium
bromide-stained 0.8% agarose gel and for amplificability by using
feline tumor necrosis factor alpha primers. PCR amplification of
env was performed as described previously (34).
For SU sequencing, DNA was amplified by nested PCR, using flanking
primers 237HS (5'-AGTAAACCCATTTAGGGTACCTG-3'; positions 6377 to 6399), 238AS (5'-CTCATCCCAGTCCACCCTTTTTTC-3'; positions
9103 to 9126), and 16AS (5'-CAGAAGAATTGATTTTGATTACA-3'; positions 8358 to 8380). Primers 237HS and 238AS were used for the first step and primers 237HS and 16AS for the second. The TM region
was amplified by single-step PCR by using the primers V4S
(5'-AACCTTTGCAATGAGAAGTT-3'; positions 7532 to 7551) and
238AS. Amplicons were then subjected to cycle sequencing using internal fluorescent-labeled primers overlapping the entire env.
Nucleotide (nt) sequences were edited and translated by PC/Gene
software (IntelliGenetics, Geel, Belgium). Selected regions were
resequenced to confirm the substitutions that distinguished the
variants. Predicted amino acid sequences were obtained with the TRANSL
program, and glycosylation sites were determined with PROSITE of the
PC/Gene package.
DNA sequences obtained from this and a previous study (7)
were aligned by using the program CLUSTAL W (46). Genetic
distance matrices were generated by using the DNADIST program of the
PHYLIP software package, version 3.5c (University of Washington,
Seattle), using Kimura's two-parameter method (20) to
correct for superimposed substitutions and a transition/transversion of
2.0. Divergence per year was calculated as follows: distance between
parental and isolate sequences at 15 months divided by 15 and
multiplied by 12.
Quasispecies analysis.
Viral RNA from virus stocks was
reverse transcribed and amplified with first-step primers pV3S
(5'-TGTTATGTAGACAGAGTAGAT-3'; positions 7113 to 7133) and
pV4AS (5'-TGCAAGACCAATTTCCAGCA-3'; positions 7847 to 7866),
and the product of this reaction was reamplified for 25 cycles with
internal primers pV4S2 (5'-TAGATGTAGATGGAATGTAG-3'; positions 7643 to 7662) and pV4AS2
(5'-CACAATAAGGTCATCTACCT-3'; positions 7789 to 7808). The
166-bp fragments of region V4 thus obtained were then subjected to
single-strand conformation polymorphism (SSCP) analysis as reported
previously (14) except that electrophoresis was carried
out in 15% nondenaturing polyacrylamide gel. Following silver staining
and washing of the gels in distilled water for at least 1 h, the
SSCP bands were excised, directly amplified, and sequenced.
Biological clones.
Biological clones were obtained using a
modification of a method previously described for HIV-1
(28). Briefly, 10 TCID50 of virus were
incubated with 5 × 106 MBM cells at 37°C in 5%
CO2 for 4 h. After thorough washing to remove any
unabsorbed virus, numbers of cells ranging from 100 to
105 were seeded into microwells containing 105
MBM cells in 100 µl of complete medium (16 wells/dilution), in order
to expand the virus produced by single infected cells. The supernatants
were monitored for p25 twice weekly for 1 month, and the ones found
positive that had been seeded with the lowest numbers of virus-exposed
cells were examined for quasispecies composition as described above.
The cultures that produced a single SSCP band were used as a source of
biologically cloned virus. The clones were expanded, filtered, frozen
in small aliquots in liquid nitrogen, subjected to titer determination,
sequenced to confirm the genotype inferred from SSCP analysis, and
examined for neutralization phenotype.
Molecular clones.
The entire env of the NS virus
cultured from cat 275 at 1 month p.i. was amplified using primers
ORFA1s (5'-GGTCGGGAGAACTATGAATGG-3'; positions 5974 to 5994)
and LPCRas (5'-GCTGTCTCCCGTTGTAGAAGTCG-3'; positions 9046 to
9069) with proofreading Expand High Fidelity DNA polymerase (Hoffman-La
Roche, Basel, Switzerland) and was cloned into the Topo TA cloning
vector (Invitrogen, Carlsbad, Calif.). Site-specific mutagenesis was
carried out on this construct by inverse PCR, using 5' phosphorylated
primers, the above polymerase, and a low number of cycles. Amplicons
were ligated with T4 DNA polymerase (New England Biolabs, Beverly,
Mass.) and were introduced into JM109 bacteria. Unaltered and
mutagenized env fragments were then inserted into p34TF10
(44), which had been rendered able to grow in lymphocytes
by removing the stop codon at position 6210 of open reading frame
A. Virus stocks were produced by transfecting into CrFK cells and
expanding in MBM cells. Proper insertion and the absence of unwanted
mutations were checked by sequencing the entire env at each step.
 |
RESULTS |
NS
NR reversion.
In a previous study, growth in vivo for 4 months had caused FIV stock FL-181 to revert to the broad
neutralization resistance typical of primary isolates (7).
To assess whether this was a constant outcome of propagating TCA FIV in
vivo, we tested for neutralization, by a panel of immune sera, three
viruses (338:36, 2906:36, and 3368:36) reisolated from cats 3 years
after infection with the same stock. All proved to be NR as primary FIV
isolates (data not shown). In contrast, additional propagation of the
producer FL4 cells for up to 24 months (variants FL-193 and FL-381) or mere passaging in MBM cells (variant 193/MBM in this study and variant
181/MBM of reference 7) had no effects on the
neutralization sensitivity of TCA FIV.
To further characterize the reversion, we studied consecutive virus
samples from three SPF cats (no. 275, 311, and 583) inoculated with
stock FL-193. The animals had become readily infected (Fig. 1); however, virus was cultured at all
times tested only from two cats. Cat 311 was uniformly provirus
positive and showed a prompt anti-FIV antibody response (Fig. 1B) but
yielded the first positive culture at 10 months p.i. Failure to
retrieve the virus from this cat at earlier time points was not
unprecedented (2, 23) and was attributed to reduced
virulence of TCA FIV for cats, as shown by relatively low provirus
loads, low or negative postacute plasma viremias, and the absence of
significant T-cell subset count changes (Fig. 1A and data not shown).
Table 1 shows the neutralization behavior
of reisolated viruses. The virus from cat 275 was as NS as the inoculum
virus at 1 and 3 months, possessed an NI phenotype at 6 months, and
scored NR at 10 and 15 months. The 10- and 15-month isolates from cat
311 both scored NR. In cat 583, the virus remained fully NS for at
least 10 months, at 15 months was NI, and at 20 months still scored as
NI although it had clearly progressed further toward global resistance.
Thus, NS
NR reversion was a constant consequence of TCA FIV
readaptation in vivo although it occurred after variably long time
intervals in individual cats. The results also showed that the
reversion could develop in a graded manner but affected in parallel the neutralizing efficiency of all panel sera, indicating that what was
being observed was indeed the reacquisition of a neutralization phenotype typical of primary FIV isolates.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Follow-up of FIV infection in three cats infected with
TCA FIV. (A) Numbers of proviruses in the peripheral blood mononuclear
cells measured by competitive PCR as described previously
(25). (B) Antibody titers to whole FIV antigen measured by
enzyme-linked immunosorbent assay (25). , cat 275; ,
cat 311; , cat 583.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Neutralizability of consecutive isolates obtained from
cats infected with TCA FIV, as determined with a panel of immune sera
|
|
Timing of NS
NR reversion relative to development of resistance
to autologous antibodies.
The consecutive viral samples described
above were also tested in checkerboard assays for neutralization by
consecutive sera derived from the same animals. Early isolates were
effectively inhibited by all sera harvested 3 or more months p.i. but
resisted neutralization by autologous sera collected at any time prior to virus reisolation. In contrast, late isolates resisted most sera and
were inhibited exclusively, and very inefficiently, by some
contemporary and subsequent autologous sera (Table
2). Thus, these findings showed that the
NS
NR reversion developed considerably later than resistance to
autologous antibodies. The analysis also showed that individual cats
had developed at least partly distinct repertoires of neutralizing
antibodies, as revealed by the partially different patterns of viral
isolates neutralized (Table 2), and that this had occurred in
concomitance with the marked decrease in circulating viral loads
observed between month 1 and 3 p.i. (Fig. 1A), thus suggesting
that neutralizing antibodies had participated in curbing the acute
phase of viral replication.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Neutralizability of consecutive virus samples obtained
from cats infected with TCA FIV by consecutive sera from the same cats
|
|
SU gene changes over time.
The SU genes (nt positions 6798 to
8097) of the above consecutive isolates and of three in vitro variants
(FL-193, 193/MBM, and FL-381) were amplified from DNA of the cells used
for viral stock production and were bidirectionally sequenced in their
entirety. None of the nt sequences obtained had premature stop
codons, deletions, or insertions, but all differed from each other
and from parental virus, indicating that they were independent.
As shown in Table 3, the 15-month
isolates from cats 275 and 311 diverged from parental virus by 0.85 and
0.70%, respectively, with an average divergence rate of 0.62% per
year. This rate was higher than the 0.41% previously found in a
long-term naturally infected cat (21) and was slightly
less than that calculated for HIV-1 and simian immunodeficiency virus
(5, 51). The 15-month isolate from cat 583 diverged from
the inoculum by only 0.15%, and this was attributable to an especially
high frequency of back mutations, as revealed by interisolate
divergence rates essentially equivalent to that observed in the other
cats. The latter rates were especially high during the first month,
most likely as a result of exuberant virus replication in the acute phase (Fig. 1) and of the virus's need to readapt to the intrahost environment, and subsequently declined, first rapidly and later more
gradually. These findings were consistent with data showing that
selective pressure for change in HIV-1 is host dependent (51) and suggested that in cat 583 the selective forces
driving virus evolution were weaker than in the other two animals,
which might explain why in this animal NS
NR reversion had occurred later than in the others. It is unfortunate that the ratio of mutated
synonymous and nonsynonymous codon sites, which might have
corroborated this conclusion, was not informative due to low total
numbers of mutations. It is also noteworthy that in cats 275 and 583, for which the time of reversion was precisely known, this occurred
during a phase of relatively slow evolution, indicating that it had
required limited mutational changes.
Figure 2 shows the SU amino acid
alignment for all the variants described above and for three similar
variants (FL-181, 181/MBM, and 3524:4mo) studied previously and
described in an earlier report (7). The SU of FIV contains
variable regions interspersed between more conserved segments
(29). Amino acid substitutions were not randomly
distributed since variation was especially high in the V3 and V4
regions. Interestingly, for V3 this was true regardless of the in vitro
or ex vivo source (Fig. 3), suggesting
that at least part of its variation might be independent of the in vivo environment, as observed for the corresponding region of HIV-1 (50). Furthermore, the V3 of the NR and NS variants
contained similar numbers of amino acid changes, in accord with the
idea that it may possibly serve as a decoy to distract the immune
system from more critical regions (6, 27, 31) but is of
less or no importance for determining global neutralization resistance. In contrast, the V4 of the NR and NI variants accumulated more changes
than the NS counterparts, hence clearly suggesting its implication in
NS
NR reversion.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
Deduced amino acid sequences of the SU of in vitro and
ex vivo variants derived from TCA FIV. Differences relative to the
progenitor virus are shown in capital letters. The neutralization
phenotype is given in parenthesis next to the variant designation.
Lines over and under sequences indicate the variable regions
(29). Numbers indicate amino acid positions starting with
the first methionine of Env, according to the reported sequence of the
34TF10 clone of FIV Petaluma (44). Potential N-linked
glycosylation sites common to all sequences are indicated by shaded
bars under the alignment, and those present in only some variants are
indicated by open boxes inside the alignment. Conserved cysteines are
undermarked by an asterisk in the progenitor sequence. Synthetic
peptides recognized by the sera of more than 50% of infected cat sera
(24) are indicated by thin lines over the progenitor
sequence to indicate the presence of linear B epitopes. Sequences
181, 181/MBM, and 3524:4mo have already been reported (7).
In sequence 583:15mo, K and N coexisted at position 481 with an
approximate ratio of 1:1.
|
|

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
Distribution of predicted amino acid changes relative to
progenitor TCA FIV in the V3, V4, and V5 regions and in the rest of the
SU of the viral variants listed in Fig. 2, grouped by source and
neutralization phenotype. The figures under the bars represent the mean
number of changes per amino acid position in the indicated SU
regions ± the standard error for the groups of variants depicted
above, while overall variation is the same parameter for all the
variants. Variable regions V3 to V5 are delineated as shown in Fig. 2.
Bars represent individual variants.
|
|
Table 4 summarizes the differential amino
acid changes detected in the NR and NI variants and not found in any of
the NS variants. Clearly, position 481 emerged as a critical residue since (i) it was substituted in each of the NR variants; (ii) it was
replaced also in the three NI variants although in one (variant
583:15mo) the replacement was incomplete; (iii) timing of the
replacement correlated with the onset of NS
NR reversion (Table 1);
(iv) in one NR and two NI variants, it was the only position
substituted, thus demonstrating that changes at this site were
sufficient to confer the NR phenotype; and (v) the other positions were
substituted in a maximum of two variants derived from a single cat,
suggesting that they may have contributed to resistance to autologous
antibodies or other immune effectors (18, 26) but played
little if any role in NS
NR reversion. Regarding the residues present
at position 481 of the NR variants, the Lys of the parental virus was
substituted for by either Asn or Glu. In the former case, the
revertants had acquired one additional potential N-linked glycosylation
site in V4. Another additional predicted glycosylation site was
present at position 469 in some ex vivo variants but did not
correlate with neutralization resistance (Fig. 2).
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Summary of differential amino acids found in NR and NI
sequential isolates and not found in any of the NS variants examined
|
|
V4 quasispecies during NS
NR reversion.
The readout of the
neutralization assay used was expected to be determined by the most
prominent variant in the virus stock. It was, therefore, of interest to
investigate whether gradual acquisition of the NR phenotype was due to
the gradual accumulation of mutations or to the time needed for the
Asn-481 and Glu-481 sequences to become sufficiently abundant. We hence
compared inoculum virus and the consecutive ex vivo isolates for
quasispecies composition in a 166-bp segment of the V4 region
encompassing position 481 (Fig. 4). The
inoculum was found to be composed of three distinct sequences in the
region examined, all with a Lys at position 481. The acute phase of
replication in vivo was characterized by a simplification of
quasispecies complexity, similar to that observed in seroconverting
HIV-1 individuals (52, 53). Subsequently, the number of
distinct sequences fluctuated between 1 and 3. It is of particular
interest, however, that Asn-481 and Glu-481 sequences first became
evident at different time points in individual hosts, initially
coexisted with Lys-481 sequences for variable times, but eventually
became the predominant (cat 583) sequence or the only one demonstrable.
Since this gradual takeover paralleled the kinetics of NS
NR
reversion (Tables 1 and 2), we concluded that the coexistence of
parental and Asn-481 or Glu-481 sequences in the viral population was
the most likely explanation for the NI phenotype.

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 4.
Quasispecies composition in the V4 region of consecutive
isolates obtained from cats infected with TCA FIV as determined by SSCP
analysis and sequencing of the resulting bands. Sequences derived from
individual bands differed in 1 to 6 nt. The ones with Lys-481 replaced
are marked E for Glu or N for Asn.
|
|
Neutralization phenotype of biological clones.
Biological
clones were derived from the NI virus cultured from cat 583 at 15 months p.i. and were studied by SSCP in the V4 region. Each clone gave
a single band in a position that, in the original uncloned virus, was
typical either of Lys-481 or Asn-481 sequences (data not shown). Four
clones selected randomly from each of these two groups were assayed for
their neutralization phenotype, and their SU was sequenced. All clones
that had given a Lys-481 band proved NS while all clones with an
Asn-481 band were NR (Table 5).
Invariably, sequence analysis of these eight clones confirmed the
genotype inferred from SSCP analysis. A similar study with the NR virus
cultured from cat 275 at 10 months p.i. led to Glu-481 clones only, as
determined by SSCP and sequence analysis, indicating a high prevalence
of this genome, and each clone proved NR (results not shown). Thus,
these findings corroborated the conclusions of quasispecies analysis.
SU sequences of putative long-term revertants.
We also
sequenced the SU of the NR variants 338:36, 2906:36, and 3368:36
(sequences available by e-mail on request), which had been obtained
from animals infected with the FL-181 stock 3 years previously (see
above) and were likely to have reverted to broad neutralization
resistance long before sampling. Lys-481 was found replaced (by Glu)
only in one of these putative long-term revertants. However, all had
Ser-557 replaced by an Asn, resulting in an additional potential
glycosylation site in V5. Although this suggested that such change was
important for neutralization resistance, each of these variants
displayed a minimum of two differential amino acids (Table 4),
rendering identification of key changes problematic.
TM sequences.
In HIV-1, changes within TM have been seen to
impact SU conformation and regulate susceptibility to selected
neutralizing antibodies (6, 27, 31, 45). In FIV, TM
changes have been seen to affect cell tropism (47), and
immunization with a TM peptide conferred some protection against
subsequent virus challenge (38). For investigating whether
TM mutations could have contributed to the reduction of virus
neutralizability, we sequenced the encoding gene of one NI and five NR
variants (sequences available by e-mail on request). One NR and one NI
variant showed no amino acid changes compared to the NS variant used as
a reference. The others showed one to three substitutions irregularly
dispersed through the extracellular, transmembrane, or intracellular
domains. In particular, there was no single position which was affected
in all the NR variants. These findings ruled out the possibility that
the TM protein played a major role in NS
NR reversion.
Neutralization phenotype of molecularly cloned viruses.
The
above data had strongly suggested that amino acid positions 481 and 557 were important in reacquisition and, possibly, maintenance of the NR
phenotype by TCA FIV. To confirm the importance of these positions, we
generated mutagenized molecular clones as described in Materials and
Methods. When transfected into CrFK cells and expanded in MBM cells,
all clones led to the production of viral stocks suitable for the
neutralization assays except the ones with Glu-481, which
for reasons
that have remained unclear
either gave a single cycle of replication
(three clones) or rapidly reverted to Lys-481 (one clone). As shown in
Table 6, Asn-481 conferred complete
resistance to all the four sera tested and Asn-557 did to only two
sera, thus suggesting that while the former change was sufficient for
broad neutralization resistance, the latter probably required the
coexistence of additional mutations.
 |
DISCUSSION |
We have approached the issue of the poor sensitivity to
antibody-mediated neutralization of wild-type lentiviruses by
investigating the evolution of an NS TCA strain of FIV upon
reinoculation into its natural host. The reversion to the NR phenotype
typical of primary isolates was a uniform outcome of readaptation in
vivo, thus indicating that this phenotype is an important survival
factor in vivo for FIV as well as for other lentiviruses (4, 5, 10, 19). That the reversion took variable numbers of months to
develop suggests that broad neutralization resistance is necessary, especially for long-term viral persistence. This, together with the
fact that all the virus variants studied grew equally well in culture
regardless of neutralization phenotype, also makes it unlikely that
substrate-controlled epigenetic changes or improved tropism for
specific target cells were important causes of NS
NR reversion
(2, 3, 8, 30, 40, 43). It is therefore plausible that
reversion was driven by the host's immune response. Accordingly, the
transition was slowest in cat 583, which also exhibited the weakest
anti-FIV enzyme-linked immunosorbent assay antibody response and the
lowest rate of SU change. The present findings also indicate that TCA
viruses should not be used as the challenge in vaccine experiments even
if repassaged in vivo for some time, unless their complete reversal to
wild-type phenotype has been verified.
Env analysis of consecutive virus samples obtained from cats infected
with the TCA FIV under study identified amino acid position 481, located centrally in the V4 region, as a key determinant of NS
NR
reversion since (i) substitution of either Asn or Glu for Lys-481 was
common to each of the virus samples with an NI or NR phenotype but was
not found in any of the NS variants; (ii) emergence and takeover of the
sequences containing these substitutions coincided temporally with the
development of the NR phenotype; and (iii) in one NR and two NI
variants, amino acid 481 was the only differential position compared to
NS variants, thus suggesting that this change alone was sufficient for
acquisition of the NR phenotype. The importance of amino acid 481 was
confirmed by the phenotype of biological and molecular clones. All
clones with Asn-481 or Glu-481 effectively resisted neutralization,
whereas the ones with Lys-481 were as NS as the TCA virus. The
additional, sporadic differential amino acids observed in some
consecutive virus samples were dispersed throughout Env and were
temporally unrelated to the transition. Thus, they may have represented
escape mutations that protected the virus from the in vivo ongoing
action of specific subsets of neutralizing antibodies and other immune effectors (18, 26, 31) but appeared unimportant for global neutralization resistance.
Studies with lentiviruses and other viruses have shown that single
amino acid substitutions, within critical linear or discontinuous epitopes or even located at a distance, can permit escape from specific immune sera or sets of monoclonal neutralizing antibodies. For
example, substituting a Leu or Thr for Ser-483 was shown to render a
molecular clone of the Amsterdam 19 strain of FIV susceptible to
neutralization by an otherwise ineffective antiserum raised against a
different clone of the same strain (41). In HIV-1, there
is also evidence that certain amino acid positions within Env control
neutralizability on a large scale (6, 27, 32). The present
findings represent the first indication that a single amino acid change
can bring about a general resistance of FIV to neutralization. Since
the diverse polyclonal sera we used to probe neutralizability are
expected to have simultaneously acted upon multiple epitopes and
clusters of epitopes and most if not all the neutralization
epitopes of wild-type FIV operative in the lymphoid cell-based
assay used here are conformation-dependent (17, 37), they
also represent evidence that distinct conformation-determining amino
acids exist within SU which prevent the functionality of multiple FIV
neutralization epitopes. The replacements of amino acid 481 associated with broad neutralization resistance resulted either in the
introduction of a potential glycosylation site (Lys
Asn) or in a
change of charge polarity (Lys
Glu), events that may have influenced
tertiary and quaternary structure, such as a condensation of SU or
altered intramolecular interactions within Env oligomeric spikes
(10, 12, 36).
It has been calculated that lentivirus-infected hosts are confronted
with every possible virus mutation on a daily basis (11). That changes at amino acid 481 were associated with NS
NR reversion in 4 of 4 hosts is, therefore, of considerable interest. Because host
cats were not siblings and their sera displayed partially different
patterns of neutralizing activity in checkerboard tests, it seems
unlikely that this was due to a stereotyped immune response. It is,
instead, more likely that changes at this position provided such a
selective advantage in vivo as to represent a highly preferable pathway
for virus evolution. Similar to what was suggested by recent findings
with TCA chimeric simian HIV (9), this in turn may imply
that the number of Env residues responsible for broad neutralization
resistance of fresh isolates is very limited. It is notable that
virtually all the SU sequenced from field FIV isolates possess an
Asn-481 irrespective of the clade in which they are classified
(34).
Finally, it is of interest that Lys-481 was found to be replaced (by an
Asn) in only 1 of 3 NR variants first reisolated from cats inoculated
with TCA FIV 3 years earlier. In such putative long-term revertants,
precise definition of the position(s) responsible for resistance was
problematic due to the presence of at least two differential SU
residues relative to NS variants. Although these revertants shared a
Ser
Asn mutation at position 557 in the V5 region, a molecular clone
with Asn-557 proved still partially neutralizable. It is, therefore,
likely that changes at this position determine the broadly resistant
phenotype only when associated with other substitutions. Because no
earlier samples of these variants were available, we cannot
discriminate whether they developed upon viruses that already had
become NR due to 481 changes, which would have demonstrated that the
genetic bases of the NR phenotype evolve with the duration of
infection, or instead stemmed directly from NS virus, which would have
shown that alternative routes to NS
NR reversion exist. A Lys
Gln
change at position 560 of V5 was previously seen to render a molecular
clone of the Amsterdam 19 strain of FIV resistant to neutralization by
an autologous antiserum (42). It is also noteworthy that
neither position 557 nor position 481 has been implicated as a
determinant of FIV tropism to different cell types (13,
22).
In conclusion, if extended to other TCA strains, the approach used here
may permit identification of Env determinants that confer broad
neutralization resistance to wild-type FIV, eventually providing leads
for the development of vaccines effective against difficult-to-neutralize strains.
We are indebted to Janet K. Yamamoto, University of Florida, for the
generous gift of FL4 cells.
| 1.
|
Baldinotti, F.,
D. Matteucci,
P. Mazzetti,
C. Giannelli,
P. Bandecchi,
F. Tozzini, and M. Bendinelli.
1994.
Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.
J. Virol.
68:4572-4579[Abstract/Free Full Text].
|
| 2.
|
Barlough, J. E.,
T. W. North,
C. L. Oxford,
K. M. Remington,
S. Dandekar,
M. N. Ellis, and N. C. Pedersen.
1993.
Feline immunodeficiency virus infection of cats as a model to test the effect of certain in vitro selection pressures on the infectivity and virulence of resultant lentivirus variants.
Antivir. Res.
22:259-272[CrossRef][Medline].
|
| 3.
|
Bastiani, L.,
S. Laal,
M. Kim, and S. Zolla-Pazner.
1997.
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions.
J. Virol.
71:3444-3450[Abstract].
|
| 4.
|
Burns, D. P. W.,
C. Collignon, and R. C. Desrosiers.
1993.
Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
J. Virol.
67:4104-4113[Abstract/Free Full Text].
|
| 5.
|
Burns, D. P. W., and R. C. Desrosiers.
1991.
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.
J. Virol.
65:1843-1854[Abstract/Free Full Text].
|
| 6.
|
Burton, D. R., and D. C. Montefiori.
1997.
The antibody response in HIV-1 infection.
AIDS
11:S87-S98.
|
| 7.
|
Cammarota, G.,
D. Matteucci,
M. Pistello,
E. Nicoletti,
S. Giannecchini, and M. Bendinelli.
1996.
Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in the V4 region of the surface glycoprotein.
AIDS Res. Hum. Retrovir.
12:173-175[Medline].
|
| 8.
|
Castilletti, C.,
M. R. Capobianchi,
S. Fais,
I. Abbate,
B. Ficociello,
F. Ameglio,
P. Cordiali Fei,
S. M. Santini, and F. Dianzani.
1995.
HIV type 1 grown on interferon -treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells.
AIDS Res. Hum. Retrovir.
11:547-553[Medline].
|
| 9.
|
Cayabyab, M.,
G. Karlsson,
B. Etemad-Moghadam,
W. Hofmann,
T. Steenbeke,
M. Halloran,
J. W. Fanton,
M. K. Axthelm,
N. L. Letvin, and J. G. Sodroski.
1999.
Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2).
J. Virol.
73:976-984[Abstract/Free Full Text].
|
| 10.
|
Cheng-Mayer, C.,
A. Brown,
J. Harouse,
P. A. Luciw, and A. J. Mayer.
1999.
Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
J. Virol.
73:5294-5300[Abstract/Free Full Text].
|
| 11.
|
Coffin, J. M.
1995.
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
Science
267:483-489.
|
| 12.
|
Davis, D.,
D. M. Stephens,
C. Willers, and P. J. Lachmann.
1990.
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acids sequence within recombinant gp120 of human immunodeficiency virus type 1.
J. Gen. Virol.
71:2889-2898[Abstract/Free Full Text].
|
| 13.
|
Dean, G. A.,
S. Himathongkham, and E. E. Sparger.
1999.
Differential cell tropism of feline immunodeficiency virus molecular clones in vivo.
J. Virol.
73:2596-2603[Abstract/Free Full Text].
|
| 14.
|
Del Mauro, D.,
D. Matteucci,
S. Giannecchini,
F. Maggi,
M. Pistello, and M. Bendinelli.
1998.
Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.
J. Virol.
72:2199-2207[Abstract/Free Full Text].
|
| 15.
|
De Ronde, A. J.,
J. G. Stam,
P. Boers,
H. Langedijk,
R. Meloen,
W. Hesselink,
L. C. E. J. M. Keldermans,
A. van Vliet,
E. J. Verschoor,
M. C. Horzinek, and H. F. Egberink.
1994.
Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralizing domain.
Virology
198:257-264[CrossRef][Medline].
|
| 16.
|
Elder, J. H., and T. R. Phillips.
1995.
Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections.
Adv. Virus Res.
45:225-247[Medline].
|
| 17.
|
Giannecchini, S.,
D. Matteucci, and M. Bendinelli.
1998.
Effect of enzymatic deglycosylation on feline immunodeficiency virus sensitivity to antibody-mediated neutralization.
AIDS Res. Hum. Retrovir.
14:199-204[Medline].
|
| 18.
|
Hosie, M. J., and J. N. Flynn.
1996.
Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.
J. Virol.
70:7561-7568[Abstract].
|
| 19.
|
Kimata, J. T.,
L. Kuller,
D. B. Anderson,
P. D. Dailey, and J. Overbaugh.
1999.
Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression.
Nat. Med.
5:535-540[CrossRef][Medline].
|
| 20.
|
Kimura, M.
1980.
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences.
J. Mol. Evol.
16:111-120[CrossRef][Medline].
|
| 21.
|
Kyaw-Tanner, M. T., and W. F. Robinson.
1996.
Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection.
Arch. Virol.
141:1703-1713[CrossRef][Medline].
|
| 22.
|
Lerner, D. L., and J. H. Elder.
2000.
Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells.
J. Virol.
74:1854-1863[Abstract/Free Full Text].
|
| 23.
|
Lombardi, S.,
C. Garzelli,
M. Pistello,
C. Massi,
D. Matteucci,
F. Baldinotti,
G. Cammarota,
L. Da Prato,
P. Bandecchi,
F. Tozzini, and M. Bendinelli.
1994.
A neutralization antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.
J. Virol.
68:8374-8379[Abstract/Free Full Text].
|
| 24.
|
Massi, C.,
S. Lombardi,
E. Indino,
D. Matteucci,
C. La Rosa,
F. Esposito,
C. Garzelli, and M. Bendinelli.
1997.
Most potential linear B-cell epitopes of Env glycoproteins of feline immunodeficiency virus are immunologically silent in mice.
AIDS Res. Hum. Retrovir.
13:1121-1129[Medline].
|
| 25.
|
Matteucci, D.,
M. Pistello,
P. Mazzetti,
S. Giannecchini,
D. Del Mauro,
I. Lonetti,
L. Zaccaro,
C. Pollera,
S. Specter, and M. Bendinelli.
1997.
Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.
J. Virol.
71:8368-8376[Abstract].
|
| 26.
|
McMichael, A. J., and R. E. Phillips.
1997.
Escape of human immunodeficiency virus from immune control.
Annu. Rev. Immunol.
15:271-296[CrossRef][Medline].
|
| 27.
|
Moore, J. P., and D. D. Ho.
1995.
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
AIDS
9:S117-S136.
|
| 28.
|
Orloff, S. L.,
C. I. Bandea,
M. S. Kennedy,
G. P. Allaway,
P. J. Maddon, and J. S. McDougal.
1995.
Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.
AIDS Res. Hum. Retrovir.
11:335-342[Medline].
|
| 29.
|
Pancino, G.,
I. Fossati,
C. Chappey,
S. Castelot,
B. Hurtrel,
A. Moraillon,
D. Klatzmann, and P. Sonigo.
1993.
Structure and variations of feline immunodeficiency virus envelope glycoproteins.
Virology
192:659-662[CrossRef][Medline].
|
| 30.
|
Park, E. J.,
M. K. Gorny,
S. Zolla-Pazner, and G. V. Quinnan.
2000.
A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
J. Virol.
74:4183-4191[Abstract/Free Full Text].
|
| 31.
|
Parren, P. W. H. I.,
J. P. Moore,
D. R. Burton, and Q. Sattentau.
1999.
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
AIDS
13:S137-S162.
|
| 32.
|
Parren, P. W. H. I.,
M. Wang,
A. Trkola,
J. M. Bilney,
M. Purtscher,
H. Katinger,
J. P. Moore, and D. R. Burton.
1998.
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
J. Virol.
72:10270-10274[Abstract/Free Full Text].
|
| 33.
|
Pedersen, N. C.
1993.
Feline immunodeficiency virus infection, p. 181-228.
In
J. A. Levy (ed.), The retroviridae, vol. 2. Plenum Press, New York, N.Y.
|
| 34.
|
Pistello, M.,
G. Cammarota,
E. Nicoletti,
D. Matteucci,
M. Curcio,
D. Del Mauro, and M. Bendinelli.
1997.
Analysis of genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates high prevalence and heterogeneity of subtype B.
J. Gen. Virol.
78:2247-2257[Abstract].
|
| 35.
|
Reed, L. J., and H. A. Müench.
1938.
A simple method for estimating fifty percent and points.
Am. J. Hyg.
27:493-497.
|
| 36.
|
Reitter, J. N.,
R. E. Means, and R. Desrosiers.
1998.
A role for carbohydrates in immune evasion in AIDS.
Nat. Med.
6:679-684.
|
| 37.
|
Richardson, J.,
I. Fossati,
A. Moraillon,
S. Castelot,
P. Sonigo, and G. Pancino.
1996.
Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope.
J. Gen. Virol.
77:759-777[Abstract/Free Full Text].
|
| 38.
|
Richardson, J.,
A. Moraillon,
F. Crespeau,
S. Baud,
P. Sonigo, and G. Pancino.
1998.
Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus.
J. Virol.
72:2406-2415[Abstract/Free Full Text].
|
| 39.
|
Ruppach, H.,
P. Nara,
I. Raudonat,
Z. Elanjikal,
H. Rübsamen-Waigmann, and U. Dietrich.
2000.
Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
J. Virol.
73:5403-5411.
|
| 40.
|
Sawyer, L. S. W.,
M. T. Wrin,
L. Crawford-Miksza,
B. Potts,
Y. Wu,
P. A. Weber,
R. D. Alfonso, and C. V. Hanson.
1994.
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.
J. Virol.
68:1342-1349[Abstract/Free Full Text].
|
| 41.
|
Siebelink, K. H. J.,
W. Huisman,
J. A. Karlas,
G. F. Rimmelzwaan,
M. L. Bosch, and A. D. M. E. Osterhaus.
1995.
Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein.
J. Virol.
69:5124-5127[Abstract].
|
| 42.
|
Siebelink, K. H. J.,
G. F. Rimmelzwaan,
M. L. Bosch,
R. H. Meloen, and A. D. M. E. Osterhaus.
1993.
A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization.
J. Virol.
67:2202-2208[Abstract/Free Full Text].
|
| 43.
|
Takeuchi, Y.,
S.-H. Liong,
P. D. Beniasz,
U. Jäger,
C. D. Porter,
T. Friedmann,
M. O. McClure, and R. A. Weiss.
1997.
Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl( 1-3)galactosylation.
J. Virol.
71:6174-6178[Abstract].
|
| 44.
|
Talbott, R. L.,
E. E. Sparger,
K. M. Lovelace,
W. M. Fitch,
N. C. Pedersen,
P. A. Luciw, and J. H. Elder.
1989.
Nucleotide sequence and genomic organization of feline immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
86:5743-5747[Abstract/Free Full Text].
|
| 45.
|
Thali, M.,
M. Charles,
C. Furman,
L. Cavacini,
M. Posner,
J. Robinson, and J. Sodroski.
1994.
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
J. Virol.
68:674-680[Abstract/Free Full Text].
|
| 46.
|
Thompson, J. D.,
D. G. Higgins, and T. J. Gibson.
1994.
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res.
22:4673-4680[Abstract/Free Full Text].
|
| 47.
|
Vahlenkamp, T. W.,
E. J. Verschoor,
N. N. M. P. Schuurman,
A. L. W. van Vliet,
M. C. Horzinek,
H. F. Egberink, and A. de Ronde.
1997.
A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism.
J. Virol.
71:7132-7135[Abstract].
|
| 48.
|
Willett, B. J.,
J. N. Flynn, and M. J. Hosie.
1997.
FIV infection of the domestic cat: an animal model for AIDS.
Immunol. Today
18:182-189[CrossRef][Medline].
|
| 49.
|
Yamamoto, J. K.,
C. D. Ackley,
H. Zochlinski,
H. Louie,
E. Pembroke,
M. Torten,
H. Hansen,
R. Munn, and T. Okuda.
1991.
Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines.
Intervirology
32:361-375[Medline].
|
| 50.
|
Yoshida, K.,
M. Nakamura, and T. Ohno.
1997.
Mutations of the HIV type 1 V3 loop under selection pressure with neutralizing monoclonal antibody NM-01.
AIDS Res. Hum. Retrovir.
13:1283-1290[Medline].
|
| 51.
|
Zhang, L.,
R. S. Diaz,
D. D. Ho,
J. W. Mosley,
M. P. Busch, and A. Mayer.
1997.
Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo.
J. Virol.
71:2555-2561[Abstract].
|
| 52.
|
Zhang, L. Q.,
P. MacKenzie,
A. Cleland,
E. C. Holmes,
A. J. Leigh Brown, and P. Simmonds.
1993.
Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.
J. Virol.
67:3345-3356[Abstract/Free Full Text].
|
| 53.
|
Zhu, T.,
H. Mo,
N. Wang,
D. S. Nam,
Y. Cao,
R. A. Koup, and D. D. Ho.
1993.
Genotypic and phenotypic characterization of HIV-1 in patients with primary infection.
Science
261:1179-1181.
|